CoolingBusiness

Pathos AI raises $237M Series E at about $3B, with Bristol Myers Squibb and Tempus AI deals

STAT reports Pathos AI, an oncology drug developer, raised a $237 million Series E at a valuation of about $3 billion, with Bristol Myers Squibb as lead investor. The BMS partnership starts with Alzheimer's treatments, and Pathos gets new datasets from Tempus AI. STAT discloses no financial terms for either deal.

HEAT
OUTLETS: 7
FIRST SEEN: Oct 23, 2026, 09:10 ET
LAST SIGNAL: 10h ago

Primary source

STATstatnews.com/2026/10/23/pathos-ai-bristol-myers-squibb-tempus-deal/

Coverage · 7 articles, oldest first

Friday, October 23, 2026

09:10
Axios
Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025
09:40
Reuters
economictimes.indiatimes.com/tech/artificial-intelligence/pathos-ai-teams-up-with-bristol-myers-and-tempus-ai-to-advance-drug-development/articleshow/135147121.cms
09:40
STAT
statnews.com/2026/10/23/pathos-ai-bristol-myers-squibb-tempus-deal/
11:40
Dow Jones Newswires
morningstar.com/news/dow-jones/202610235869/tempus-ai-expands-bristol-myers-partnership-with-multi-year-oncology-ai-data-deals
15:40
Pulse 2.0
pulse2.com/pathos-ai-raises-237-million-series-e-at-3-billion-valuation-to-advance-ai-driven-oncology-pipeline/
16:02
SiliconANGLE
AI drug development startup Pathos AI closes $237M investment
16:10
MarketWatch
marketwatch.com/story/tempus-ai-expands-bristol-myers-partnership-with-multi-year-oncology-ai-data-deals-df88726c

ShareX LinkedIn Hacker News Email

← The whole wire